Literature DB >> 28703393

Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis.

T Schmidt1, M Hoch1, S S Lotfi Jad1, F Solimani1, G Di Zenzo2, A V Marzano3, M Goebeler4, E Cozzani5, J S Kern6, C Sitaru6, I Lakoš Jukić7, M Sárdy8, S Uzun9, H Jedlickova10, R Gläser11, M Kaneda12, R Eming1, G Göpel1, N Ishii13, B Greene14, T Hashimoto13, M Hertl1.   

Abstract

BACKGROUND: Epidermolysis bullosa acquisita (EBA) is a rare, potentially devastating autoimmune disease of the skin. IgG autoantibodies directed against type VII collagen (Col7), the major component of anchoring fibrils, induce skin fragility leading to cutaneous and mucocutaneous blister formation, which is mostly of a scarring phenotype. Thus, powerful and reproducible diagnostic assays are critical to establish the diagnosis of EBA early to avoid irreversible sequelae.
OBJECTIVES: The present international, retrospective multicentre study included a large cohort of patients with EBA and evaluated the diagnostic power of four different diagnostic assays for the detection of anti-Col7 IgG autoantibodies.
METHODS: Overall, 95 EBA sera and 200 control sera consisting of 100 bullous pemphigoid sera, 50 pemphigus vulgaris sera and 50 sera of healthy controls were tested for anti-Col7 IgG autoantibodies using indirect immunofluorescence (IIF), two commercial enzyme-linked immunosorbent assay (ELISA) systems and Western blot (WB) analysis. EBA sera were taken from patients with positive direct immunofluorescence and IgG reactivity in at least one of the immunoserological assays (IIF, ELISA, WB).
RESULTS: A Col7-NC1/NC2 ELISA (MBL, Nagoya, Japan) showed the highest sensitivity (97·9%), followed by a Col7-NC1 ELISA (Euroimmun, Lübeck, Germany) (89·5%), WB with Col7-NC1 (85·3%), and IIF on saline-split human skin (74·7%). The specificities of both ELISA systems were comparable (NC1 98·7%, NC1/NC2 99·3%). Furthermore, WB was more sensitive than IIF, which was more specific.
CONCLUSIONS: The two commercially available ELISA systems allow for a highly sensitive and specific diagnosis of EBA. The sensitivity of the Col7-NC1/NC2 ELISA is significantly higher compared with the ELISA based on the Col7-NC1 domain only.
© 2017 British Association of Dermatologists.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28703393     DOI: 10.1111/bjd.15800

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  10 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

2.  Diagnosis of Epidermolysis Bullosa Acquisita: Multicentre Comparison of Different Assays for Serum Anti-type VII Collagen Reactivity.

Authors:  Maike M Holtsche; Nina van Beek; Takashi Hashimoto; Giovanni Di Zenzo; Detlef Zillikens; Catherine Prost-Squarcioni; Matthias Titeux; Alain Hovnanian; Enno Schmidt; Stephanie Goletz
Journal:  Acta Derm Venereol       Date:  2021-03-23       Impact factor: 3.875

3.  Diagnostic Value and Practicability of Serration Pattern Analysis by Direct Immunofluorescence Microscopy in Pemphigoid Diseases.

Authors:  Maike M Holtsche; Nina van Beek; Axel Künstner; Hauke Busch; Detlef Zillikens; Enno Schmidt
Journal:  Acta Derm Venereol       Date:  2021-03-09       Impact factor: 3.875

4.  Frequency of Envoplakin and Type VII Collagen Autoantibodies and Co-occurrence with Other Skin-specific Autoantibodies in HIV-infected Patients and Uninfected Controls.

Authors:  René Reitermaier; Michael Skoll; Veronique Touzeau-Roemer; Maximilian C Aichelburg; Adelheid Elbe-Bürger; Wolfgang Bauer; Armin Rieger; Christopher Schuster
Journal:  Acta Derm Venereol       Date:  2021-11-24       Impact factor: 3.875

5.  Accessible Diagnostic Methods to Differentiate between Epidermolysis Bullosa Acquisita and Other Subepidermal Autoimmune Bullous Diseases.

Authors:  Khalaf Kridin
Journal:  Indian J Dermatol       Date:  2018 Sep-Oct       Impact factor: 1.494

Review 6.  Serological Diagnosis of Autoimmune Bullous Skin Diseases.

Authors:  Sandra Saschenbrecker; Ingolf Karl; Lars Komorowski; Christian Probst; Cornelia Dähnrich; Kai Fechner; Winfried Stöcker; Wolfgang Schlumberger
Journal:  Front Immunol       Date:  2019-08-20       Impact factor: 7.561

7.  Case Report: Diagnostic and Therapeutic Challenges in Severe Mechanobullous Epidermolysis Bullosa Acquisita.

Authors:  Franziska Schauer; Alexander Nyström; Manfred Kunz; Stefanie Hübner; Sarah Scholl; Ioannis Athanasiou; Svenja Alter; Judith Fischer; Cristina Has; Dimitra Kiritsi
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

8.  Anti-Type VII Collagen Antibodies Are Identified in a Subpopulation of Bullous Pemphigoid Patients With Relapse.

Authors:  Delphine Giusti; Grégory Gatouillat; Sébastien Le Jan; Julie Plée; Philippe Bernard; Frank Antonicelli; Bach-Nga Pham
Journal:  Front Immunol       Date:  2018-03-21       Impact factor: 7.561

Review 9.  Epidermolysis Bullosa Acquisita: The 2019 Update.

Authors:  Hiroshi Koga; Catherine Prost-Squarcioni; Hiroaki Iwata; Marcel F Jonkman; Ralf J Ludwig; Katja Bieber
Journal:  Front Med (Lausanne)       Date:  2019-01-10

10.  European Guidelines (S3) on diagnosis and management of mucous membrane pemphigoid, initiated by the European Academy of Dermatology and Venereology - Part II.

Authors:  E Schmidt; H Rashid; A V Marzano; A Lamberts; G Di Zenzo; G F H Diercks; S Alberti-Violetti; R J Barry; L Borradori; M Caproni; B Carey; M Carrozzo; G Cianchini; A Corrà; F G Dikkers; C Feliciani; G Geerling; G Genovese; M Hertl; P Joly; J M Meijer; V Mercadante; D F Murrell; M Ormond; H H Pas; A Patsatsi; S Rauz; B D van Rhijn; M Roth; J Setterfield; D Zillikens; G Zambruno; B Horváth; F Caux
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-07-26       Impact factor: 6.166

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.